Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,452 signal articles · 144 in last 24h · 154,112 total before filter · latest 21m ago
144last 24h
877last 7d
147● bullish (7d)
98● bearish (7d)
214publishers
AllMacro210Earnings108M&A125Regulatory22Product21Analyst17
✕ clear all filtersticker: MRKSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
Insider Monkey1d agoneutral
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO

AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
Insider Monkey20d agoneutral
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
Insider Monkey28d agobullish
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]

Organon & Co. Shareholders Clear Sun Pharma Merger Deal
MarketBeat63d agoneutral
Organon & Co. Shareholders Clear Sun Pharma Merger Deal

Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons

Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger
Insider Monkey90d agobullish
Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger

Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion. In a statement, Bio-Techne Corp. (NASDAQ:TECH) said […]

How America Got to SpaceX: The Long Trail of Big IPOs That Began in 1783
Barrons.com99d agoneutral
How America Got to SpaceX: The Long Trail of Big IPOs That Began in 1783

SpaceX’s $75 billion initial public offering shattered market records, turned founder Elon Musk into the world’s first trillionaire, and opened fresh debates over corporate valuations and governance. It’s not the first time an IPO has shaken things up. IPOs have been reshaping markets since the Bank of North America’s 1783 debut got it all started for the young republic.